Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study.
about
Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary managementEpidemiology and Inherited Predisposition for Sporadic Pancreatic AdenocarcinomaNew insights into pancreatic cancer-induced paraneoplastic diabetesDeterminants of concentrations of N(ε)-carboxymethyl-lysine and soluble receptor for advanced glycation end products and their associations with risk of pancreatic cancerSerum glucose and fructosamine in relation to risk of cancerDietary consumption of advanced glycation end products and pancreatic cancer in the prospective NIH-AARP Diet and Health Study.Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology.The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer.Circulating Leptin and Risk of Pancreatic Cancer: A Pooled Analysis From 3 Cohorts.Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory diseaseSoluble receptor for advanced glycation end products and risk of liver cancer.Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer.Dietary glycotoxins and infant formulas.Effect of RAGE gene polymorphisms and circulating sRAGE levels on susceptibility to gastric cancer: a case-control study.Lysyl Oxidase and the Tumor MicroenvironmentGlycative stress from advanced glycation end products (AGEs) and dicarbonyls: An emerging biological factor in cancer onset and progression.Pioglitazone, a PPARγ agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling.Serum B6 vitamers (pyridoxal 5'-phosphate, pyridoxal, and 4-pyridoxic acid) and pancreatic cancer risk: two nested case-control studies in Asian populations.Insulin resistance is associated with the aggressiveness of pancreatic ductal carcinoma.HMGB1: A Promising Therapeutic Target for Prostate Cancer.The role of S100A12 as a systemic marker of inflammation.Circulating soluble advanced glycation end product is inversely associated with the significant risk of developing cancer: evidence from a meta-analysis.Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy.Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.Advanced Glycation End Products in the Pathogenesis of Psoriasis.Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients.Long-term physical activity leads to a significant increase in serum sRAGE levels: a sign of decreased AGE-mediated inflammation due to physical activity?A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women.Anti-Hypertensive Medication Use, Soluble Receptor for Glycation End Products and Risk of Pancreatic Cancer in the Women's Health Initiative Study
P2860
Q26781156-6E8FF206-016E-48F5-B0F3-E4DA9CCBCCD7Q26801418-67CCC2D7-15B0-4067-8B6E-14F71DA5EA23Q27687766-97D545C2-A131-4240-96B8-19DF0AE9BE0AQ34426525-812118F0-AF38-426A-8748-30BC14424161Q34571468-857C584F-AA8B-4CEC-9D78-0EB5D1850396Q34706565-989D60FB-1BFF-48D5-936F-C4C5F8150160Q35140467-D1E2A924-4845-49FD-BE6E-1DC98928A4C8Q35752134-C0CF6116-10C2-4EC5-AFB7-9253C7B5B2BFQ35896957-A9188E98-B50C-4B53-96B7-030A038EF199Q35991574-E930AFA6-654D-4E09-9248-DBCFE13CA32EQ36816945-E32B29E4-44D5-4EA0-9179-39A14924571EQ37021217-19ED7AF4-36B7-4F62-83A1-B4BDA580F7F0Q37591929-A2FEB067-CD25-441B-B403-73D72A59D577Q37627994-8F3B3AF1-3F15-4BF4-8907-3DACDC924B49Q37631469-A226DE52-BBE7-4B13-872C-8C2850AAA98BQ38698770-88A11469-832B-4A71-8D95-CB4E35A70116Q38948698-2C3B3FA9-3B43-42B9-A4C0-4A642A515141Q40481663-A669BCCB-B0F1-4D9B-8D0F-9CDFB7BB101BQ40610844-498B580C-57AB-4DE8-A0B3-12BFB450FCB9Q41136849-D57B3BCD-01A3-40BF-9592-E54C6F8D8828Q42234262-E38D42D8-88E0-4C59-8431-839F9F12EAC2Q43742322-671EB350-D25C-4917-AB14-6E0A9A1CFDCCQ44844478-D917D690-7623-4709-B4BA-071F654C2F67Q45796080-C87792DB-2BE8-4E80-AC31-9768B612544AQ46257931-13737767-F33D-47C6-8D42-45FF1077C080Q46430969-11D666E3-A407-4AAC-9A48-1E665AA1E22DQ48170304-A3881A69-D71A-49EB-9E4A-C7A87996289DQ52638887-32AC5972-478F-46C0-A9C6-432EDCB5B00CQ57171167-003AEB33-A84F-43A8-8A4D-E8E93E3371A6
P2860
Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Evidence that serum levels of ...... cer risk: a prospective study.
@ast
Evidence that serum levels of ...... cer risk: a prospective study.
@en
Evidence that serum levels of ...... cer risk: a prospective study.
@nl
type
label
Evidence that serum levels of ...... cer risk: a prospective study.
@ast
Evidence that serum levels of ...... cer risk: a prospective study.
@en
Evidence that serum levels of ...... cer risk: a prospective study.
@nl
prefLabel
Evidence that serum levels of ...... cer risk: a prospective study.
@ast
Evidence that serum levels of ...... cer risk: a prospective study.
@en
Evidence that serum levels of ...... cer risk: a prospective study.
@nl
P2093
P2860
P50
P1433
P1476
Evidence that serum levels of ...... cer risk: a prospective study.
@en
P2093
Barry I Graubard
Philip R Taylor
Stephanie J Weinstein
P2860
P304
P356
10.1158/0008-5472.CAN-10-2573
P407
P577
2011-05-03T00:00:00Z